{
  "docId": "019de076-b731-71da-a78f-007719e300bb",
  "docSlug": "1616e8b22ac58e7f024f1153201d610f",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 42,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "The slide uses a chronological structure to demonstrate operational momentum.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b731-71da-a78f-007719e300bb/5",
  "deckHref": "/decks/019de076-b731-71da-a78f-007719e300bb",
  "deckJsonHref": "/decks/019de076-b731-71da-a78f-007719e300bb.json",
  "deckAnchorHref": "/decks/019de076-b731-71da-a78f-007719e300bb#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.94,
        "x": 0.03,
        "y": 0.205
      },
      "kind": "callout",
      "text": "Resource-efficient execution and value creation across an expanding portfolio of wholly-owned programs",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cc23f679-c88d-46b0-af67-5f9114d3795a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.06,
        "y": 0.36
      },
      "kind": "list",
      "text": "2021: EMERGENCE FROM STEALTH. Disclosed parallel lead programs (ROS1+ and ALK+ NSCLC). Presented preclinical profiles. Nasdaq listed: NUVL.",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "046450ce-0fad-4eed-8f79-c42f9c4567c5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.36,
        "y": 0.36
      },
      "kind": "list",
      "text": "2022: FIRST CLINICAL PROOF-OF-CONCEPT. Initiated two global Phase 1/2 studies. Demonstrated clinical proof-of-concept for ROS1 program. Disclosed third novel program (HER2 NSCLC).",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2abfa1c7-97e9-4b8d-9388-c2b7b388f0e5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.66,
        "y": 0.36
      },
      "kind": "list",
      "text": "2023: SECOND PROOF-OF-CONCEPT & FIRST PIVOTAL STUDY. Demonstrated clinical proof-of-concept for ALK program. Initiated ARROS-1 Phase 2 with registrational intent. Advanced HER2 program towards IND.",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2cc18fa1-b779-4d56-87af-a4c5b8846678",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.15,
        "y": 0.79
      },
      "kind": "paragraph",
      "text": "Ended 2023 with approximately $719.9M* in cash, cash equivalents and marketable securities (unaudited), with potential to deliver multiple transformative catalysts within cash runway window into 2027",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7994f3ca-7303-41ab-af8b-3e493b3bb5f4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.9,
        "x": 0.05,
        "y": 0.89
      },
      "kind": "source-note",
      "text": "* Preliminary, unaudited estimate only as of the date of this presentation; subject to change following completion of year-end closing procedures; does not present all information necessary for an understanding of financial position as of December 31, 2023.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fac7327d-fc97-45e8-9c28-9a6a1c35d122",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.36,
        "x": 0.32,
        "y": 0.1
      },
      "kind": "title",
      "text": "Track Record of Success",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "92deb3a2-ade4-438a-a845-dd0347cabec7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "2f12ac16-fdd0-4d69-ba8d-4cc23ea189b1",
      "evidence": "Chronological presentation of milestones from 2021-2023",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 10,
      "from": 4,
      "beatId": "1b4ba678-72a5-41ab-80a1-d0e9467146f7",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The deck presents Nuvalent's approach as a potential solution to the problem.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}